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Abstract  82 
To ensure efficient genome duplication, cells have evolved numerous factors that 83 
promote unperturbed DNA replication, and protect, repair and restart damaged forks.  84 
Here we identify DONSON as a novel fork protection factor, and report biallelic 85 
DONSON mutations in 29 individuals with microcephalic dwarfism. We demonstrate that 86 
DONSON is a replisome component that stabilises forks during genome replication. Loss 87 
of DONSON leads to severe replication-associated DNA damage arising from nucleolytic 88 
cleavage of stalled replication forks. Furthermore, ATR-dependent signalling in response 89 
to replication stress is impaired in DONSON-deficient cells, resulting in decreased 90 
checkpoint activity, and potentiating chromosomal instability. Hypomorphic mutations 91 
substantially reduce DONSON protein levels and impair fork stability in patient cells, 92 
consistent with defective DNA replication underlying the disease phenotype.  93 
In summary, we identify mutations in DONSON as a common cause of 94 
microcephalic dwarfism, and establish DONSON as a critical replication fork protein 95 
required for mammalian DNA replication and genome stability.  96 
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Microcephalic primordial dwarfism (MPD) is the collective term for a group of human 97 
disorders characterised by intra-uterine and postnatal growth delay alongside marked 98 
microcephaly1, and includes disorders such as MOPD II, ATR/ATRIP-Seckel syndrome 99 
and Meier-Gorlin syndrome. Mutations in genes encoding either components of the DNA 100 
replication machinery (replisome) or genome stability proteins are a frequent cause of 101 
microcephalic dwarfism2-14. 102 
During the course of normal DNA replication, a subset of replication forks may stall, 103 
causing ‘replication stress’15. This stalling can be caused by endogenous or exogenous 104 
sources, such as collision of the replisome with DNA lesions or the transcriptional 105 
machinery, or replication of difficult to replicate genomic regions. To facilitate efficient 106 
genome duplication, stalled replication forks must be stabilised and protected from 107 
collapse. Multiple factors safeguard replication fork stability, many of which function within 108 
the ATR-CHK1-dependent replication stress response16-18. This pathway ensures that fork 109 
stabilisation is tightly coordinated with a global reduction in DNA synthesis, allowing stalled 110 
or damaged forks to be repaired and restarted19,20. 111 
Exome sequencing analysis of microcephalic dwarfism patients has identified 112 
several novel factors that regulate replication and/or the replication stress response. Using 113 
this strategy, we recently identified mutations in TRAIP in individuals with MPD5, and 114 
demonstrated that TRAIP is required for the response to replication-blocking DNA lesions. 115 
To identify similar disease-associated genes, we carried out whole exome sequencing of 116 
genetically uncharacterised patients with microcephaly. Here, we report the identification 117 
of DONSON as a new microcephalic dwarfism gene, and demonstrate that DONSON is a 118 
novel replisome component that maintains genome stability by protecting stalled/damaged 119 
replication forks.  120 
7  
Results 121 
DONSON mutations identified in microcephalic dwarfism patients 122 
Whole exome sequencing (WES) was undertaken on 26 patients with microcephaly 123 
and reduced stature. After aligning WES reads to the reference genome, variant calling, 124 
and filtering for rare variants (MAF <0.005), analysis under a recessive model of 125 
inheritance identified rare biallelic variants in the DONSON (‘Downstream neighbour of 126 
SON’) gene in nine affected individuals from seven families. Sanger capillary sequencing 127 
confirmed the presence of these mutations in these patients (P1-1 to P3, P6, and P9 to 128 
P11, Table 1). Subsequent re-sequencing of an additional 230 patients with primary 129 
microcephaly, microcephaly with reduced stature, or MPD, identified five additional 130 
families with compound heterozygous mutations in DONSON (P4, P5, P7, P8, P12; Table 131 
1). All variants segregated amongst family members in a manner consistent with an 132 
autosomal recessive trait, and were present at a frequency of <0.5% in the ExAC 133 
database21. 134 
Two other concurrent molecular genetic studies provided further independent 135 
evidence to support the identification of DONSON as a novel human disease gene. Firstly, 136 
exome sequencing was carried out on a consanguineous Palestinian family previously 137 
reported to have a Fanconi Anaemia-like disorder22. These patients presented with 138 
microcephaly, short stature, slow growth and forearm and thumb dysplasia, although no 139 
individuals had haematological evidence of bone marrow failure. This WES analysis 140 
revealed a deleterious homozygous transition, c.1337T>C, resulting in substitution of a 141 
highly conserved residue (p.M446T) in all three affected individuals (P13-1, P13-2, P13-3; 142 
Table 1, Supplementary Fig. 1). Secondly, a study of five consanguineous families in 143 
Saudi Arabia with extreme microcephaly and short stature allowed a 1.6 Mb haplotype 144 
shared by all five families (combined multipoint LOD score Z= 8.0) to be mapped to a 145 
defined critical interval on chromosome 21 that contained DONSON. Whole exome and 146 
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genome sequencing identified a single rare variant at this locus in DONSON, c.786-22A>G. 147 
Capillary sequencing confirmed this intronic variant to be homozygous in all seven affected 148 
individuals from this study (P14 to P18-3; Table 1), identical to that detected in two Saudi 149 
Arabian individuals present within the first study described above (P11, P12). 150 
Subsequently, a further five individuals from three different families with DONSON 151 
mutations were identified in additional MPD patients recruited to two of the genetic studies 152 
described above (P19 to P21-2; Table 1). 153 
DONSON mutations give rise to severe microcephaly with short stature 154 
Despite their identification in separate studies, all patients with DONSON mutations 155 
had similar clinical phenotypes. Marked microcephaly was present (OFC -7.5 +/- 2.4 SD), 156 
with a substantial reduction in cerebral cortical size, along with decreased gyral folding 157 
evident on neuroimaging (Fig. 1a and Supplementary Fig. 2), similar to that previously 158 
reported for other primary microcephaly and microcephalic dwarfism patients5,23-25. Height 159 
was reduced (-3.2 +/- 1.4 SD), although much less so than head circumference (Fig. 1a), 160 
and to a lesser degree than observed in other microcephalic dwarfism-associated 161 
disorders (where height was typically ≤ -4 SD)2,3,5,8-10,24,26. Minor skeletal abnormalities 162 
were present in several patients, including fifth finger clinodactyly, syndactyly, 163 
brachydactyly, hypoplasia of carpal/metacarpal/phalangeal bones, or radial head 164 
dislocation (Supplementary Table 1). Absent/hypoplastic patellae were present in 165 
patients P12, P20-1 and P20-2. Notably, patient P19 had bilateral hypoplasia of the radius 166 
and thumb, which, together with the limb abnormalities displayed by P13-1 and 13-2, 167 
established radial ray defects as an uncommon but recurrent phenotype. In family P21, the 168 
most extreme phenotype was observed, with substantial limb shortening/reduction in 169 
association with foetal lethality (Supplementary Fig. 3). Aside from microcephaly, neither 170 
a recognisable facial phenotype (Fig. 1b) nor recurrent malformations affecting other 171 
organ systems were evident. Intellectual disability, if present, was typically mild.  172 
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In conclusion, the number of biallelic variants identified, combined with a common 173 
clinical presentation, provided strong evidence for DONSON being a novel human disease 174 
gene, associated with autosomal recessive inheritance. We therefore investigated the 175 
consequence of these mutations on DONSON protein function. 176 
 177 
DONSON mutations markedly reduce protein levels 178 
DONSON mutations were identified in 29 individuals, and comprised a range of 179 
mutation classes (Fig. 1c). Notably, no biallelic nonsense or frameshift mutations were 180 
observed, indicating that mutations likely resulted in partial loss of DONSON function. To 181 
investigate this, we established patient-derived primary fibroblast or lymphoblastoid cell 182 
lines representing a range of mutations. Immunoblotting demonstrated marked decreases 183 
in DONSON protein levels in all cell lines tested (Fig. 2a, b), establishing that the analysed 184 
mutations affected DONSON protein expression. 185 
Mutations in multiple families were associated with two different ancestral 186 
haplotypes (P1-1 to P7; P11, P12 and P14 to 18-3 respectively; Table 1) and were 187 
investigated in more detail. Firstly, as described above, nine individuals (P11, P12 and 188 
P14 to P18-3) were homozygous for the c.786-22A>G mutation, predicted to enhance a 189 
cryptic splice donor site within intron 4 (MaxEntScan)27. Consistent with a common 190 
ancestral founder, five consanguineous families of Saudi Arabian origin bearing this 191 
mutation (P14 to P18-3) shared a 1.6 Mb haplotype region of chromosome 21 192 
(Supplementary Fig. 4). qRT-PCR analysis of RNA isolated from four patients with this 193 
variant demonstrated a significant decrease in full-length transcript, and increased 194 
skipping of exon 5 (Supplementary Fig. 5). This resulted in an out-of-frame mRNA 195 
predicted to undergo NMD, explaining the substantial reduction in protein levels seen in 196 
fibroblasts homozygous for this mutation (P12; Fig 2b).  197 
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Secondly, two missense variants in DONSON, p.S28R and p.K489T, and an 198 
intronic variant (c.786-33A>G) were present in seven individuals of European ancestry and 199 
one Somali (P1-1 to P7; Table 1). These were associated with a different ancestral 200 
haplotype, comprising a shared 127.7 kb genomic region (Supplementary Table 2). No 201 
other deleterious biallelic variants were present in the four other genes within this region. 202 
Despite the close proximity of the c.786-33A>G intronic variant to the Saudi Arabian c.786-203 
22A>G mutation, the former change did not disrupt splicing between exons 4 and 5, as 204 
assessed by either mini gene splicing assays (Supplementary Fig. 6), or RT-PCR 205 
analyses of patient cell lines (data not shown), indicating this variant is unlikely to be 206 
pathogenic. Since DONSON protein levels were severely reduced in cells from patients 207 
inheriting this haplotype allele in combination with a truncating mutation (P2, P6), this 208 
suggested that either one or both of the missense variants associated with this haplotype 209 
(p.S28R, p.K489T) compromised protein levels (Fig. 2b). 210 
To investigate these two variants, we established isogenic HeLa cell lines 211 
expressing doxycycline-inducible, siRNA-resistant wild type (WT) or mutant (p.S28R, 212 
p.K489T) GFP-tagged DONSON. Following siRNA depletion of endogenous DONSON 213 
(Supplementary Fig. 7), and induction of exogenous GFP-DONSON, immunoblotting 214 
revealed that the p.K489T mutation, but not p.S28R, reduced protein levels in a post-215 
transcriptional manner (Fig. 2c and Supplementary Fig. 8). This suggested that the 216 
p.K489T substitution within the second haplotype causes the decreased DONSON protein 217 
levels observed in P2 and P6 (Fig. 2b). The K489T variant is present as a rare allele in the 218 
population, observed at a frequency of 0.00099 in the ExAC database21. In the patients 219 
reported here, it is always observed in trans with a frameshift or other protein-disrupting 220 
allele, suggesting that it is a functionally weak variant insufficient to cause disease alone, a 221 
conclusion supported by the presence of a single homozygous individual in ExAC.   222 
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Eight other point mutations were identified in patients: six missense substitutions, a 223 
two amino-acid deletion and an amino-acid insertion (Table 1 and Fig. 1c). Notably these 224 
were at highly conserved residues (Supplementary Fig. 1) and predicted to be 225 
deleterious (Alamut Visual). In agreement, exogenous expression of the p.M446T mutant 226 
resulted in significantly reduced protein levels (Fig. 2c), similar to cells derived from 227 
patients P13-1, P13-2 and P13-3. Furthermore, five of these mutations disrupted the 228 
subcellular localisation of GFP-DONSON (Supplementary Fig. 9), suggesting that these 229 
alterations also compromise DONSON protein function via protein mis-localisation.  230 
Finally, an intronic mutation, c.1047-9A>G, was present in three individuals (P9, 231 
P21-1 and P21-2). qRT-PCR analysis of RNA isolated from the two patients homozygous 232 
for this variant (P21-1, P21-2) revealed a substantial reduction in DONSON transcript 233 
levels compared to normal controls (Supplementary Fig. 10). This variant was also 234 
observed in trans with the missense mutation F292L in patient P9. Since cells derived from 235 
this individual exhibited severely reduced levels of DONSON protein (Fig. 2b), it is likely 236 
that this intronic change also perturbs DONSON protein expression. 237 
Taken together, the deleterious consequences of the identified mutations on 238 
splicing, transcript abundance, subcellular localisation and/or protein levels strengthened 239 
our conclusion that DONSON was a novel human disease gene. The fact that knockout of 240 
murine Donson leads to developmental lethality28, together with the presence of residual 241 
DONSON protein in patient-derived cell lines (Fig. 2a, b and Supplementary Fig. 11), 242 
supports the notion that the identified mutations are hypomorphic, retaining some residual 243 
function.  244 
 245 
DONSON stabilises replication forks during normal DNA replication 246 
While DONSON is highly conserved in metazoa and plants, its precise function(s) 247 
remained to be defined. Humpty-dumpty (hd), the Drosophila ortholog of DONSON, has 248 
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been proposed to play a role in cell proliferation: Hd expression peaks during S-phase; hd 249 
mutants have an ‘egg shell’ phenotype; and clonal inactivation of hd impairs genome 250 
replication in larval tissues29.  251 
In light of this, we investigated whether human DONSON might play a similar role. 252 
After synchronising cells with a double thymidine block, we observed that human 253 
DONSON, like Hd, was also maximally expressed during S-phase, mirroring Cyclin A 254 
expression (Fig. 3a). Furthermore, depletion of DONSON resulted in a significant increase 255 
in BrdU-positive cells observed by FACS, consistent with a role in promoting efficient S-256 
phase progression (Fig. 3b). Given these data, we next used DNA fibre analysis to assess 257 
whether DONSON depletion led to decreased DNA replication fork progression. Although 258 
fork progression rates did not decrease in cells lacking DONSON (Fig. 3c), compromising 259 
DONSON expression increased spontaneous replication fork stalling, with a concomitant 260 
decrease in the number of ongoing forks (Fig. 3d). Moreover, we also observed increased 261 
replication fork asymmetry in cells depleted of DONSON, indicating replication fork 262 
instability (Fig. 3e). Together, this suggests that the increase in BrdU-positive DONSON-263 
depleted cells may reflect prolonged S-phase due to stalled replication forks, rather than a 264 
global reduction in DNA synthesis. 265 
Since DNA replication is closely linked with genome stability15,30,31, we reasoned 266 
that loss of DONSON would lead to a failure to complete timely replication and increased 267 
S-phase DNA damage. To test this hypothesis, we combined immunofluorescence of γ-268 
H2AX and 53BP1 (markers of DNA damage and DNA double strand breaks respectively) 269 
with EdU labelling to identify S-phase cells. We observed that a significant proportion of 270 
DONSON-depleted cells exhibited spontaneous γ-H2AX and 53BP1 foci (Fig. 3f), of which 271 
the majority occurred in S-phase cells (Supplementary Fig. 12a-d), consistent with the 272 
identification of DONSON as a potential genome stability regulator by high-throughput 273 
siRNA screening32. Using pulsed-field gel electrophoresis, we also observed elevated 274 
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levels of DNA double strand breaks in the absence of DONSON (Supplementary Fig. 275 
12e). Taken together, these data support a role for DONSON in maintaining replication 276 
fork stability during unperturbed DNA replication, and demonstrate that spontaneous DNA 277 
damage arises in replicating cells in the absence of DONSON. 278 
 279 
DONSON is a component of the replisome 280 
To shed further light on the role of DONSON in regulating replication fork stability, 281 
we carried out mass spectrometry screening to identify interaction partners of GFP-tagged 282 
DONSON. Amongst the interactors, we detected multiple replication proteins including 283 
subunits of the MCM helicase and the GINS complex (Fig. 4a and Supplementary Table 284 
3). To confirm these findings, we carried out pull-down analyses coupled with 285 
immunoblotting to identify GFP-DONSON binding proteins. Consistent with our mass 286 
spectrometry data, we detected interactions between GFP-DONSON and the replisome 287 
components MCM2, MCM7, Treslin and PCNA (Fig. 4b), suggesting that DONSON 288 
associated with the replisome. 289 
 We next used three complementary techniques to assess whether DONSON 290 
localised to sites of DNA replication. Firstly, we carried out proximity ligation assays (PLA) 291 
of GFP-DONSON with the replication proteins PCNA and RPA. In line with DONSON 292 
being closely associated with the replication machinery, we observed robust PLA signals 293 
between GFP-DONSON and both PCNA and RPA (Fig. 4c, d). We next performed 294 
Fluorescence Cross-Correlation Spectroscopy (FCCS)33,34 in live HeLa cells stably co-295 
expressing RFP-PCNA and GFP-DONSON, to measure the degree of co-diffusion of 296 
these molecules. Significantly increased co-diffusion of PCNA and DONSON was 297 
observed in S-phase PCNA foci, but not in nuclei of non-replicating cells (Fig. 4e-f and 298 
Supplementary Fig. 13), indicating that these proteins interacted during DNA replication. 299 
Finally, we utilised iPOND (isolation of proteins on nascent DNA)35 combined with mass 300 
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spectrometry to ascertain whether DONSON is present on newly replicated DNA. Crucially, 301 
this approach demonstrated that DONSON, like MCMs and RPA, was significantly 302 
enriched at replication forks compared to mature chromatin (Fig. 4g).  303 
 Collectively, these data strongly support the conclusion that DONSON is a novel 304 
replisome component that plays a role in promoting fork stability. 305 
 306 
DONSON depletion impairs cell-cycle checkpoint activation  307 
Since our data suggested that DONSON functions to protect replication forks during 308 
unperturbed DNA replication, we extended our findings to evaluate the role of DONSON in 309 
preventing replication fork stalling following exogenous replication stress. Exposure to the 310 
replication stress-inducing agents hydroxyurea (HU) and mitomycin C (MMC) induced 311 
significantly more fork stalling in DONSON-depleted cells than in control cells (Fig. 5a-b). 312 
DONSON depletion also resulted in a failure to suppress new origin firing upon exogenous 313 
replication stress (Fig. 5c). Since suppression of new origin firing reflects checkpoint 314 
activity, this suggests that DONSON is required for efficient activation of the intra-S phase 315 
checkpoint. To further investigate this, we measured activation of this checkpoint after 316 
inhibition of ATR (VE821; ATRi), the apical kinase which governs the replication stress 317 
response18. Upon HU exposure and ATR inhibition, we observed no difference in the 318 
number of new origins fired between control or DONSON-depleted cells, indicating that 319 
DONSON and ATR may function within the same pathway to activate the intra-S phase 320 
checkpoint (Fig. 5d). 321 
We next examined whether the ATR-dependent replication stress response was 322 
functional in the absence of DONSON. We first monitored ATR pathway activation in 323 
DONSON-depleted cells treated with HU or MMC by immunoblotting, using phospho-324 
specific antibodies to known ATR substrates. This analysis revealed that cells lacking 325 
DONSON failed to efficiently phosphorylate a number of ATR substrates, such as CHK1 326 
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and NBS1, in response to HU or MMC (Fig. 5e and Supplementary Fig. 14a). Moreover, 327 
ATR autophosphorylation on T1989, another marker of ATR activation36, was reduced 328 
(Supplementary Fig. 14b). Loss of DONSON also significantly increased mitotic indices 329 
following exposure to HU or MMC as measured by FACS, demonstrating that DONSON-330 
depleted cells fail to efficiently activate the G2/M checkpoint in response to replication 331 
stress (Fig. 5f and Supplementary Fig. 14c). We next determined whether the reduced 332 
ATR signalling observed was due to decreased levels of RPA-coated ssDNA, which is the 333 
stimulus for ATR activation. Surprisingly, DONSON-depleted cells exhibited elevated 334 
levels of RPA-coated ssDNA following HU treatment (Supplementary Fig. 15), consistent 335 
with defective activation of the ATR-dependent replication stress response. 336 
Dysregulated DNA replication combined with impaired intra-S phase checkpoint 337 
signalling, such as in ATR-deficient cells37-41, gives rise to extensive chromosome 338 
breakage and genome instability. Consistent with this, we observed significantly elevated 339 
levels of spontaneous micronuclei and chromatid gaps/breaks in cells lacking DONSON 340 
(Fig. 6a and Supplementary Fig. 16a), which was exacerbated by exposure to HU or 341 
MMC (Supplementary Fig. 16a-c). We also observed spontaneously-arising highly-342 
fragmented or completely pulverised metaphase chromosomes in cells lacking DONSON, 343 
which increased upon exogenous replication stress (Fig. 6b and Supplementary Fig. 344 
16d). 345 
Together, these data confirm that upon exogenous replication stress, DONSON is 346 
required to stabilise stalled replication forks, efficiently activate the intra-S and G/2M cell-347 
cycle checkpoints, and maintain genome stability. 348 
 349 
Cleavage of stalled replication forks in DONSON-deficient cells 350 
It has been proposed that the spontaneous DNA damage arising in ATR-deficient 351 
cells is due to processing of stalled/damaged forks by SLX4-associated structure-specific 352 
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nucleases, such as MUS81, SLX1 and XPF42-46. We therefore postulated that the 353 
replication abnormalities and chromosomal aberrations of DONSON-deficient cells might 354 
arise via similar mechanisms. Indeed, the spontaneous replication fork asymmetry and 355 
H2AX phosphorylation exhibited by DONSON-depleted cells were partially reduced by co-356 
depletion of either MUS81 or XPF (Fig. 6c, d). Moreover, co-depletion of MUS81 or XPF 357 
also reduced chromosome breakage and genomic pulverisation in these cells (Fig. 6e-g). 358 
From this, we conclude that the severe genome instability apparent in the absence of 359 
DONSON is due to nucleolytic processing of damaged replication forks by structure-360 
specific nucleases. 361 
 362 
Replication stress-induced genomic damage in DONSON patient cells 363 
To link the role of DONSON in regulating replication fork stability and the phenotype 364 
of patients with DONSON mutations, we characterised replication dynamics and genomic 365 
stability of patient-derived fibroblasts. All DONSON patient-derived cell lines examined (P2, 366 
P6, P9, P10-2, P12) showed higher levels of spontaneous fork asymmetry and fork stalling 367 
than cells from unaffected individuals (Supplementary Figs. 17a, 18). Furthermore, 368 
patient-derived cells also exhibited elevated fork asymmetry and fork stalling following HU 369 
exposure, combined with defective intra-S phase checkpoint activation (Supplementary 370 
Fig. 17a, 18). Finally, levels of S-phase DNA damage and chromosome breakage were 371 
also elevated in these cell lines (Supplementary Fig. 17b-c). Together, these 372 
observations provide a potential pathological explanation for the clinical phenotype. 373 
In addition, using isogenic cell lines inducibly expressing GFP-DONSON (Fig. 2c), 374 
we observed that expression of the haplotype-associated S28R mutant, but not the K489T 375 
variant, complemented loss of endogenous DONSON by rescuing the spontaneous fork 376 
stalling observed upon DONSON depletion (Supplementary Fig. 19). This is consistent 377 
with K489T being the pathogenic variant within the haplotype region (Fig. 2c). 378 
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Finally, we set out to demonstrate that the patient-associated cellular phenotypes 379 
were directly due to mutation of DONSON. We first established three paired isogenic cell 380 
lines via transduction of patient-derived fibroblasts with retroviral expression vectors 381 
encoding WT DONSON or an empty vector (Fig. 7a). Importantly, the spontaneous DNA 382 
damage, replication fork stalling, replication fork asymmetry and intra-S phase checkpoint 383 
defect were all corrected by expression of WT DONSON (Fig. 7b-d and Supplementary 384 
Fig. 20), confirming that these phenotypes were directly due to DONSON deficiency. 385 
Lastly, using one of these cell lines, we also observed that inhibition of ATR and mutation 386 
of DONSON are epistatic with regard to the observed replication abnormalities 387 
(Supplementary Fig. 21).  388 
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Discussion 389 
Here we identify DONSON as a novel human disease gene, and describe 29 390 
individuals with a range of mutations in DONSON, establishing such alterations as a 391 
frequent cause of microcephalic dwarfism. Since normal embryonic development requires 392 
rapid cellular proliferation47,48 it is exquisitely sensitive to genetic perturbations that impact 393 
DNA replication1-3,6. A failure to complete timely genome duplication will profoundly affect 394 
the number of cells generated during embryonic development. For example, hypomorphic 395 
mutations in ATR result in severe microcephaly and growth retardation, both in humans 396 
and in a murine model2,3,49,50, due to the role that ATR plays in preventing replication 397 
stress during development49-50. We propose that mutation of DONSON similarly reduces 398 
the number of cells generated during development via a failure to maintain replication fork 399 
stability in the presence of endogenous replication stress, thus explaining the decreased 400 
organism size observed. Furthermore, since brain development requires rapid proliferation 401 
of neural progenitor cells within a limited timeframe47, it is particularly sensitive to 402 
disruptive genetic perturbations. This may explain why brain development is 403 
disproportionately affected in these individuals compared to growth. 404 
DONSON has no predicted domain structure or paralogs, and previous 405 
characterisation has been limited to two previous studies: an siRNA screen proposing that 406 
DONSON regulates genome stability, and a study of its Drosophila ortholog Humpty-407 
dumpty suggesting a role in cell proliferation29,32. Consistent with this, we establish that 408 
DONSON is a replisome component that ensures replication fork stability, and promotes 409 
efficient activation of both intra-S and G2/M cell-cycle checkpoints upon exogenous 410 
replication stress. Loss of DONSON leads to increased spontaneous stalling of replication 411 
forks, which are subsequently cleaved into replication-associated DNA double strand 412 
breaks by structure-specific nucleases. Defective cell-cycle checkpoint activation in 413 
DONSON-deficient cells then allows transmission of these breaks into mitosis, accounting 414 
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for the elevated chromosomal damage and genome fragmentation observed 415 
(Supplementary Fig. 22). Additional studies will be important to confirm this model, and to 416 
investigate whether DONSON is a constitutive component of the replisome, or whether it is 417 
recruited to a subset of replication forks. Furthermore, establishing which replisome 418 
components DONSON directly interacts with, and the functional importance of these 419 
associations, will also inform understanding of its biological function. 420 
The mechanism by which DONSON ensures replication fork stability and promotes 421 
checkpoint activation remains to be defined. We propose that in addition to being a 422 
replisome component, DONSON is also involved in promoting the ATR-CHK1 replication 423 
stress response, since we observed that DONSON-depleted cells exhibit defective 424 
activation of cell cycle checkpoints and reduced ATR-dependent signalling in response to 425 
exogenous replication stress. This hypothesis is supported by the observation that 426 
impaired replication alone, such as that arising from a hypomorphic mutation in MCM4 427 
(MCM4Chaos3/Chaos3), does not give rise to decreased CHK1 phosphorylation or increased 428 
new origin firing upon replication stress51. However, it is unclear whether DONSON 429 
functions directly or indirectly to regulate the ATR-CHK1 pathway. Our demonstration that 430 
cells lacking DONSON do not exhibit a global reduction in replication, or decreased levels 431 
of RPA-coated ssDNA, indicates that loss of DONSON does not affect the cells ability to 432 
generate the primary stimulus for ATR pathway activation. Based on this, we propose that 433 
either DONSON directly activates ATR, in a manner similar to TOPBP152 or ETAA153,54, or 434 
functions indirectly to regulate other factors necessary for efficient ATR-CHK1 signalling, 435 
such as the MRE11/RAD50/NBS1 (MRN)55 complex or TIPIN/Timeless19,20. Since 436 
DONSON does not contain a canonical ATR activation domain, which is found in both 437 
TOPBP1 and ETAA1, we favour the latter possibility. However, how DONSON acts to 438 
promote ATR signalling is not yet clear, and future work will be critical in establishing 439 
whether this is direct or indirect. 440 
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It is also evident that the cellular phenotype of cells lacking DONSON cannot be 441 
explained solely by abnormal DNA replication or defective ATR-dependent signalling. In 442 
particular, exposure of cells lacking ATR to exogenous replication stress results in highly 443 
elevated levels of H2AX phosphorylation, a situation not observed upon DONSON loss 444 
(Fig. 5e), despite the presence of substantial amounts of DNA damage. Therefore, whilst 445 
our observations are consistent with a role for DONSON in promoting ATR-CHK1 446 
signalling, DONSON may also impact on other pathways that promote H2AX 447 
phosphorylation at the replication fork, for example those governed by ATM or the MRN 448 
complex. 449 
 In summary, we have identified DONSON as a novel disease gene that plays a key 450 
role in regulating cellular replication and cell cycle checkpoints. Further studies examining 451 
how DONSON functions will provide fundamental insight into how cells maintain replication 452 
fork integrity, and how these pathways prevent human disease.  453 
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Figure Legends:   618 
Figure 1: DONSON mutations cause severe microcephaly and short stature.  619 
(a) DONSON mutations result in severe prenatal-onset microcephaly, often associated 620 
with short stature. Length at birth (Lgt), current height (Hgt) and head circumference (OFC) 621 
plotted as z-scores (SD from population mean for age and sex). Black horizontal bars 622 
indicate mean values. Dashed line at -2 SD indicates cut-off for normal population 623 
distribution. Patients from the three independently identified DONSON patient cohorts are 624 
denoted by black (P1-P12 and P20), orange (P13), and blue (P14-19 and P21) circles. (b) 625 
Photographs of affected individuals with DONSON mutations demonstrating facial 626 
similarities. Written consent to publish photographs was obtained from the affected 627 
families. P, patient. (c) Schematics of the DONSON gene and protein indicating position of 628 
the identified mutations. DONSON mutations comprised a range of mutation classes 629 
(nonsense, frameshift, essential splice site, missense and intronic). The genomic structure 630 
is based on the longest ORF containing ten coding exons (white rectangles) 631 
(NM_017613.3). The positions of identified mutations affecting splicing are shown on the 632 
gene structure (top) and missense and truncating variants on the encoded protein (bottom).  633 
 634 
Figure 2: Mutations in DONSON affect protein levels. 635 
(a-b) DONSON mutations result in severely reduced levels of DONSON protein. 636 
Immunoblotting of cell extracts from lymphoblastoid (a) and fibroblast (b) cell lines derived 637 
from patients with mutations in DONSON. ATR was used as a loading control. The two 638 
blots from (a) originate from two independent gels. (c) The K489T, but not the S28R 639 
variant, associated with the DONSON haplotype affects protein levels. Cells were treated 640 
with doxycycline 48 h post siRNA transfection, and harvested for Western blot analysis 24 641 
h later (n=2). Exogenous DONSON were detected using an anti-GFP antibody 642 
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respectively. TOPBP1 was used as a loading control. Depletion of endogenous DONSON 643 
in these cells was confirmed by immunoblotting (Supplementary Fig. 2). 644 
 645 
Figure 3. Loss of DONSON results in spontaneous replication fork stalling and 646 
increased genome instability. 647 
(a) DONSON protein levels are increased during S-phase. HeLa cells were synchronised 648 
in S-phase using a double thymidine block, released, harvested at the indicated time 649 
points, and immunoblotting was performed (n=2). Cyclin A and phospho-histone H3 Ser-650 
10 are markers of S/G2 and M phase respectively. Vinculin represents a loading control. 651 
(b) S-phase is prolonged upon DONSON depletion. HeLa cells transfected with the 652 
indicated siRNAs were pulsed with BrdU, fixed and analysed by FACS (n=4; error bars 653 
indicate SD). (c-e) Replication fork analysis of HeLa cells transfected with control or 654 
DONSON siRNA and pulsed with CldU and IdU. (c) Top: Schematic of DNA fibre analysis. 655 
Bottom: loss of DONSON does not decrease replication fork velocity. Replication fork 656 
speed (kb/min) was determined (n=5). (d) DONSON depletion results in spontaneous fork 657 
stalling. Percentages of ongoing replication forks, new origins and stalled replication forks 658 
in cells from (c) were quantified (n=3). (e) DONSON depletion leads to replication fork 659 
asymmetry. Top: example images; magenta arrows indicate origins of replication; white 660 
arrow denotes fork asymmetry. Bottom: plot indicates the ratio of left/right fork track 661 
lengths of bidirectional replication forks in cells from (c). Red lines denote median ratios 662 
(n=3). (f) Loss of DONSON increases spontaneous γH2AX/53BP1 foci formation. HeLa 663 
cells transfected with the indicated siRNAs were immunostained with antibodies to 53BP1 664 
and γH2AX (left panel), and the percentage of cells with >10 53BP1 and γH2AX foci were 665 
quantified using fluorescence microscopy (right panel; n=5; >300 cells per sample per 666 
independent experiment). Scale bar; 10 µm.  667 
 668 
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Figure 4. DONSON localizes to the replication fork. 669 
(a-d) DONSON interacts with multiple components of the replication machinery. (a) GFP 670 
or GFP-DONSON was precipitated by GFP-Trap, from asynchronous cells or cells 671 
accumulated in S-phase with 2 mM HU treatment for 24 h. Heatmap denotes significant 672 
interactions identified by mass spectrometry (n=3). Inset: Schematic of the mammalian 673 
replisome with selected replication factors. (b) 293FT cells were transfected with the 674 
indicated expression vectors in the presence/absence of HU. GFP or GFP-DONSON were 675 
isolated by GFP-Trap and co-precipitating proteins visualised by immunoblotting (n=2). 676 
Benzonase Nuclease was included to exclude DNA-mediated interactions. The bottom two 677 
panels are scanned images of Ponceau S-stained nitrocellulose membrane. (c-d) 678 
DONSON localises in close proximity to replication forks. (c-d) PLA was carried out on 679 
cells from (a) using the indicated antibodies in the presence/absence of HU (n=2). (c) 680 
Quantification of PLA signals. (d) Representative PLA images. (e-f) DONSON interacts 681 
with PCNA at replication foci in live cells. (e) Representative confocal images of live cells 682 
expressing GFP-DONSON and RFP-PCNA. Boxes indicate representative regions used 683 
for FCCS analysis. (f) FCCS measurements of GFP-DONSON and RFP-PCNA reveal 684 
significant cross-correlation at replication foci at similar concentrations. Average cross-685 
correlation curves are shown from cells expressing GFP-DONSON in replication foci (red) 686 
or non-replicating (grey) cells, or GFP-expressing S-phase nuclei (purple). Inset: Mean 687 
cross-correlation amplitude values from multiple cells (error bars indicate SD; n=4, 3 and 688 
5). Increased G(τ) values indicate higher degree of cross-correlation between GFP-689 
DONSON and RFP-PCNA in replication foci. See also Supplementary Fig. 11. (g) iPOND 690 
was performed on 293T (n=3), HeLa (n=2) and HCT116 (n=2) cells, and EdU-691 
coprecipitates analysed by mass spectrometry. Data represents the combination of all 692 
seven experiments. Log2 abundance denotes the ratio of proteins at nascent DNA 693 
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compared to mature chromatin. Values >0 represent proteins enriched at forks, whilst 694 
values ≤0 denote chromatin-bound factors. Scale bars; 10 µm.  695 
 696 
Figure 5. Depletion of DONSON compromises activation of cell cycle checkpoints. 697 
(a-c) Loss of DONSON results in replication fork instability that is exacerbated by 698 
replication stress. (a) HeLa cells transfected with either control or DONSON siRNA were 699 
pulsed with CldU, exposed to 2 mM HU for 2 h, and then pulsed with IdU. Alternatively, 700 
cells were exposed to 50 ng/ml MMC for 24 h, and pulsed with sequential pulses of CldU 701 
and IdU (see schematic). DNA fibres were quantified, and the percentage of (b) stalled 702 
forks and (c) new origins are displayed (in all cases n=3). (d) Loss of DONSON is epistatic 703 
with ATR inhibition. Replication fork analysis of HeLa cells transfected with either control 704 
or DONSON siRNA. Cells were pulsed with CldU, exposed to 2 mM HU +/- 5μM ATR 705 
inhibitor for 2 h, and then pulsed with IdU (n=3). New origins (2nd label origin) were 706 
counted as an indicator of intra-S phase checkpoint activation. (e) Cells lacking DONSON 707 
exhibit defective or delayed ATR activation in response to replication stress. Whole cell 708 
extracts of HeLa cells transfected with either control or DONSON siRNA were subjected to 709 
immunoblot analysis using the indicated antibodies following treatment with 1 mM HU 710 
(n=2). (f) The percentage of mitotic cells following exposure to 1 mM HU for 24 h (from (e)) 711 
was determined by flow cytometry, using antibodies to phosphorylated histone H3-Ser10 712 
(a marker of mitosis) (n=5).  713 
 714 
Figure 6. Increased spontaneous chromosome breakage and fragmentation of 715 
mitotic chromosomes in DONSON-depleted cells. 716 
(a,b) Metaphases chromosomes from DONSON or control siRNA transfected HeLa cells 717 
were visualised by Giemsa staining and light microscopy. (a) Quantification of average 718 
numbers of chromatid gaps/breaks per metaphase (n=6; >50 metaphases per sample per 719 
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experiment). (b) Representative images of normal chromosomes, chromosomes 720 
containing gaps/breaks, highly fragmented and pulverized chromosomes. Red arrows 721 
denote chromatid gaps/breaks; blue arrows indicate chromosomal exchanges. Scale bar; 722 
10 µm. (c-g) Loss of the structure-specific nucleases MUS81 or XPF significantly reduces 723 
the spontaneous replication fork asymmetry and genome instability in DONSON-depleted 724 
cells. (c) Cells transfected with the indicated siRNAs were pulsed with CldU and IdU. 725 
Replication fork asymmetry was measured as in (Fig. 3e). The red lines denotes median 726 
ratios (n=3). (d) Co-depletion of MUS81 or XPF with DONSON reduces levels of 727 
spontaneous DNA damage. Extracts from cells transfected with the indicated siRNAs were 728 
subjected to SDS-PAGE and immunoblotting using the antibodies indicated. (e-f) Co-729 
depletion of MUS81 (e) or XPF (f) reduces chromosomal aberrations in cells lacking 730 
DONSON. Quantification of the average number of chromatid gaps/breaks per metaphase 731 
in cells transfected with control, DONSON, MUS81 and/or XPF siRNA. At least 50 732 
metaphases per experiment were counted (n=3). (g) Quantification of the average 733 
percentage of metaphases containing highly fragmented chromosomes or pulverized 734 
chromosomes in cells transfected with the indicated siRNAs. At least 50 metaphases per 735 
experiment were counted (n=3). 736 
 737 
Figure 7: DONSON patient cells have spontaneous defects in replication fork 738 
progression that result in DNA damage 739 
(a) Complementation of patient-derived fibroblasts with WT DONSON. Fibroblasts derived 740 
from DONSON patients P2, P6 and P9 were infected with retroviruses encoding either WT 741 
DONSON or an empty vector. DONSON expression was determined by immunoblotting. A 742 
non-specific cross-reactive protein represents a loading control. (b) Expression of WT 743 
DONSON in patient fibroblasts rescues elevated levels of spontaneous DNA damage. The 744 
percentage of cells from (a) with 53BP1/γH2AX foci was quantified by immunostaining 745 
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(n=3). (c) DNA fibre analysis of complemented DONSON patient fibroblasts pulsed with 746 
CldU and IdU. Fork asymmetry was quantified. Plot indicates ratios of left/right fork track 747 
lengths of bidirectional replication forks. The red lines denote median ratios. (n=3). (d) The 748 
percentage of stalled forks and new origins from cells in (c) was quantified (n=3). Ongoing 749 
forks are shown in (Supplementary Fig. 19). 750 
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Table 1:  Biallelic DONSON mutations identified in 29 individuals 
 
Patient Country of Origin Mutation 1 Mutation 2 Segregation 
P1-1 Italy c.1251_1256delCTCTAA, p.Asn417_Ser418del haplotype Het, M 
P1-2 Italy c.1251_1256delCTCTAA, p.Asn417_Ser418del haplotype Het, M 
P2 UK c.877C>T, p.Arg293* haplotype Het, M, P 
P3 UK c.1254dupT, p.Lys419* haplotype Het, M, P 
P4 UK c.1686dupT, p.Asn563* haplotype Het, nps 
P5 Somalia c.832T>C, p.Cys278Arg AND/OR c.845A>G, p.Tyr282Cys haplotype Het, M, P 
P6 USA c.1282C>T, p.Gln428* haplotype Het, M, P 
P7 USA c.1282C>T, p.Gln428* haplotype Het, nps 
P8 Italy c.1474_1475delCA, p.Gln492Glufs*18 c.786-7T>C Het, M, P 
P9 Turkey c.876C>G, p.Phe292Leu c.1047-9A>G (SS) Het, M 
P10-1 India c.1628_1630dupAAA, p.Gln543_Ile544insLys c.1032C>T, p.Ser344Ser (SS) Het, M, P 
P10-2 India c.1628_1630dupAAA, p.Gln543_Ile544insLys c.1032C>T, p.Ser344Ser (SS) Het, M, P 
P11 Saudi Arabia c.786-22A>G (SS) c.786-22A>G (SS) Hom, M, P 
P12 Saudi Arabia c.786-22A>G (SS) c.786-22A>G (SS) Hom, nps 
P13-1 Palestine c.1337T>C, p.Met446Thr c.1337T>C, p.Met446Thr Hom, M, P 
P13-2 Palestine c.1337T>C, p.Met446Thr c.1337T>C, p.Met446Thr Hom, M, P 
P13-3 Palestine c.1337T>C, p.Met446Thr c.1337T>C, p.Met446Thr Hom, M, P 
P14 Saudi Arabia c.786-22A>G (SS) c.786-22A>G (SS) Hom, M, P 
P15 Saudi Arabia c.786-22A>G (SS) c.786-22A>G (SS) Hom, M, P 
P16 Saudi Arabia c.786-22A>G (SS) c.786-22A>G (SS) Hom, M, P 
P17 Saudi Arabia c.786-22A>G (SS) c.786-22A>G (SS) Hom, M, P 
P18-1 Saudi Arabia c.786-22A>G (SS) c.786-22A>G (SS) Hom, M, P 
P18-2 Saudi Arabia c.786-22A>G (SS) c.786-22A>G (SS) Hom, M, P 
P18-3 Saudi Arabia c.786-22A>G (SS) c.786-22A>G (SS) Hom, M, P 
P19 Turkey c.1297C>T, p.Pro433Ser c.1297C>T, p.Pro433Ser Hom, M, P 
P20-1 South Africa c.1254dupT, p.Lys419* c.1510G>A, p.Glu504Lys Het, M, P 
P20-2 South Africa c.1254dupT, p.Lys419* c.1510G>A, p.Glu504Lys Het, M, P 
P21-1 Saudi Arabia c.1047-9A>G (SS)  c.1047-9A>G (SS) Hom, M, P 
P21-2 Saudi Arabia c.1047-9A>G (SS)  c.1047-9A>G (SS)  Hom, M, P 
 
‘Haplotype’ indicates the presence of three co-segregating variants: c.82A>C (p.Ser28Arg); c.786-
33A>G; c.1466A>C (p.Lys489Thr). Hom, homozygous in affected individual; Het, compound 
heterozygous in affected individual; M, mutation identified in mother; P, mutation identified in father; 
nps, no parental samples available; SS, Splice site mutation. Reference sequence, NM_017613.3. 
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Online Methods 759 
Research subjects. 760 
Genomic DNA from the affected children and family members was extracted from 761 
peripheral blood using standard methods or saliva samples using Oragene collection kits 762 
according to the manufacturer's instructions. Informed consent was obtained from all 763 
participating families. Ethics for the studies were approved by the Scottish Multicentre 764 
Research Ethics Committee (04:MRE00/19), by an IRB-approved research protocol 765 
(KFSHRC RAC# 2080006), and via the ’National Gene Mapping’ protocol by Guy’s and St. 766 
Thomas’ National Health Service (NHS) Foundation Trust local research ethics committee 767 
(ref.: 08/H0802/84, “Systematic Characterization of Genes in Inherited Disorders”). In 768 
addition, ethical approval for linkage studies on the genetics of Fanconi anaemia in 1989 769 
were obtained from the Guy’s Hospital Research Ethics Committee (ref. EC89/10/27)22, 770 
with further approval for mutation analysis on existing samples in 1996 (ref. 96/3/9).   771 
Parents provided written consent for the publication of photographs of the affected 772 
individuals. 773 
 774 
Exome sequencing and haplotype analysis. 775 
Exome sequencing of genomic DNA and variant filtering was performed as described 776 
previously12. Cohort resequencing was performed by Sanger sequencing of PCR products 777 
representing all coding exons of DONSON (primer sequences are detailed in 778 
Supplementary Table 4), with variant calling using MutationSurveyor (SoftGenetics Inc.). 779 
Haplotype analysis was undertaken by SNP genotyping both patients using Affymetrix 780 
CytoScan 750K arrays. Genotypes were generated using Affymetrix Genotyping Console 781 
software and examined manually. The pathogenic impact of DONSON mutations was 782 
predicted using Alamut Visual Software (Interactive Biosoftware Inc). 783 
 784 
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Cell culture and generation of cell lines. 785 
Lymphoblastoid cell lines (LCLs) were maintained in RPMI 1640 supplemented with 15% 786 
FBS, L-glutamine and penicillin/streptomycin antibiotics. LCLs were generated in house 787 
from peripheral blood samples by EBV transformation using standard methods. Dermal 788 
primary fibroblasts were grown from skin-punch biopsies in AmnioMax medium (Life 789 
Technologies) and then maintained in DMEM supplemented with 10% FBS, 5% L-790 
glutamine and 5% penicillin/streptomycin antibiotics. Patient cell lines were validated using 791 
Sanger sequencing and immunoblotting. 293FT (Invitrogen) and HeLa (ATCC) cells were 792 
maintained in DMEM supplemented with 10% FBS, 5% L-glutamine and 5% 793 
penicillin/streptomycin antibiotics. 794 
 795 
Stable cell lines were generated by Flp recombinase–mediated integration using HeLa-796 
Flp-In T-REx host cells (gift from S. Taylor, University of Manchester) transfected with 797 
pcDNA5/FRT/TO-EGFP (vector only or EGFP-TRAIP) and pCAGGS-Flp.e (gift from D.-J. 798 
Kleinjan, University of Edinburgh). Transfected cells were selected using 5 μg/ml 799 
blasticidin and 400 μg/ml hygromycin, and the resulting colonies were then expanded for 800 
testing. Protein expression was induced with 1 μg/ml doxycycline (Sigma-Aldrich) 801 
treatment.  802 
 803 
Primary fibroblasts derived from patients 2, 6 and 9 were immortalized with TERT retroviral 804 
supernatant with 4 μg/ml polybrene and infected with pMSCV-vector only or pMSCV-805 
DONSON. Selection was performed using 750 ng/ml puromycin (Clontech) and 500 μg/ml 806 
neomycin (Invitrogen). Expression of the protein was verified by immunoblotting (Fig. 7a). 807 
All cell lines were routinely tested for mycoplasma. 808 
 809 
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Cell treatments. 810 
Plasmids and siRNA oligos were transfected in Opti-MEM reduced serum medium using 811 
Lipofectamine 2000 and Oligofectamine (Life Technologies) respectively according to the 812 
manufacturer's guidelines. A custom siRNA targeting lacZ has previously been described56, 813 
and was used as a control siRNA. A DONSON siRNA SMARTpool (Dharmacon) was used 814 
for all siRNA transfections except when transfecting the HeLa Flp-In/T-Rex cells 815 
expressing an exogenous, siRNA-resistant, GFP-tagged DONSON construct. In this case 816 
a custom DONSON siRNA sequence (CCTGTGGACTGGAGTATTAdTdT) was used 817 
(Dharmacon). MUS81 siRNA SMARTpool and XPF siRNA SMARTpool (Dharmacon) were 818 
used where indicated. Transfected cells in both cases were analysed at 48-72 h post 819 
transfection. Where indicated, cells were treated with 1-2 mM hydroxyurea (Sigma-Aldrich), 820 
50 ng/ml mitomycin C (Sigma-Aldrich) or 2 mM thymidine (Sigma-Aldrich). The ATR 821 
inhibitor (VE-821; Selleck Chemicals) was used at 5 μM. dNTP analogues EdU, CldU and 822 
IdU were purchased from Sigma Aldrich, and were used as indicated. 823 
 824 
RT-PCR. 825 
Total RNA was extracted from cell lines using the RNeasy kit (Qiagen) according to the 826 
manufacturer's instructions. DNA was removed by treatment with DNase I (Qiagen), and 827 
cDNA was generated using random oligomer primers and AMV RT (Roche). The RT-PCR 828 
primer pairs used are detailed in Supplementary Table 4. 829 
 830 
DNA expression constructs 831 
pEGFP-DONSON expression construct was created by cloning the human DONSON ORF 832 
into the pDONR221 Gateway shuttle vector (Invitrogen).  WT DONSON was amplified 833 
from cDNA and recombined into the pDEST-EGFP vector to generated a GFP-tagged 834 
DONSON expression construct. The DONSON ORF was made siRNA resistant using site-835 
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directed mutagenesis (Agilent Technologies) by altering the following nucleotides: 836 
CCTGTGGACTGGAGTATTA was changed to CCCGTAGATTGGTCTATCA. Patient-837 
associated mutations were engineered into the pEGFP-DONSON expression plasmid 838 
using site-directed mutagenesis according to the manufacturer’s instructions. (All primers 839 
are detailed in Supplementary Table 4). 840 
 841 
The retroviral expression construct expressing DONSON was created by recombination 842 
between the pDONR221-DONSON vector and a Gateway-compatible pMSCVneo 843 
retroviral expression construct (Clontech). 844 
 845 
The human telomerase reverse transcriptase (hTERT) expressing retroviral construct used 846 
to immortalise patient-derived human fibroblasts was a kind gift from Bob Weinberg 847 
(Addgene plasmid: #1771). 848 
 849 
Minigene splicing reporter assay 850 
A 1.58 kb stretch of the DONSON gene encompassing the 3’ end of intron 3, exon 4, 851 
intron 4, exon 5 and the 5’ end of intron 5 was amplified using DNA from a healthy 852 
individual and DONSON patients (carrying mutation c.786-22A>G or c.786-33A>G) using 853 
the DONSON-int3-SalI-F and DONSON-int5-SpeI-R primers, and cloned into the RHCglo 854 
vector57 using the SalI and SpeI restriction sites. Site-directed mutagenesis was used to 855 
introduce the DONSON intron 4 splice acceptor mutation (c.786-1G>A) into the splicing 856 
reporter construct. HeLa cells were transfected with each individual splicing mutation 857 
reporter construct using Lipofectamine 2000 according the manufacturer’s instructions. 24 858 
h post-transfection, cells were harvested, total cellular RNA was extracted and cDNA 859 
generated using Superscript III reverse transcriptase first-stand synthesis system 860 
(Invitrogen). PCR was carried out using primers (RSV_minigene_F and RSV_minigene_R) 861 
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to the 5’ and 3’ ends of the artificial exons present in the RHCglo vector. DONSON WT 862 
and mutant cDNA amplicons were resolved on a 2% agarose gel to visualise differences in 863 
splicing. Individual PCR products were subsequently cloned into the pGEM-T Easy Vector 864 
(Promega) and sequenced to verify the exon content of each transcript. All relevant 865 
primers are detailed in Supplementary Table 4. 866 
 867 
iPOND 868 
iPOND was performed as previously described35,58. Briefly, exponentially growing cells 869 
were incubated with 10 µM EdU for 10 min, cross-linked with 1% formaldehyde, harvested 870 
and permeabilised. For pulse-chase controls, cells were incubated in 10 µM EdU for 10 871 
min, washed in media containing 10 µM thymidine, then incubated with media containing 872 
10 µM thymidine for 1 h, before being cross-linked. Biotin azide was covalently attached to 873 
EdU within newly replicated DNA using a Click reaction, and EdU containing DNA was 874 
precipitated using Streptavidin agarose beads. Edu co-precipitates were then analysed by 875 
mass spectrometry. Log2 abundance values represent the ratio of proteins found in EdU-876 
pulsed samples compared to those pulse-chased with EdU-thymidine. 877 
 878 
Immunoblot analysis and antibodies 879 
Whole cell extracts were obtained by sonication in UTB buffer (8 M Urea, 50 mM Tris, 150 880 
mM β-mercaptoethanol) and analysed by SDS-PAGE following standard procedures. 881 
Protein samples were run on 6-12% acrylamide SDS-PAGE or 4-12% NuPage mini-gels 882 
(Life Technologies) and transferred onto nitrocellulose membrane. Immunoblotting was 883 
performed using antibodies to: Cyclin A (Santa Cruz, sc-751; 1:1,000), CHK1 (Santa Cruz, 884 
sc-8408; 1:1,000), CHK2 (Santa Cruz, sc-5278; 1:1000), FANCD2 (Santa Cruz, sc-20022; 885 
1:1000), MCM2 (BD Transduction Laboratories, 610700; 1:10000), MCM7 (Santa Cruz, 886 
sc-56324; 1:1000), MUS81 (Santa Cruz, sc-53382; 1:2000); XPF (Santa Cruz, sc-136153; 887 
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1:1000); H2A (Millipore, 07-146; 1:3000), γ-H2AX (Millipore, 05-636; 1:3000), RPA2 888 
(Millipore, NA18; 1:1000), phospho-histone H3 Ser-10-P (Millipore); pS343-NBS1 (Abcam, 889 
47272; 1:500); NBS1 (Genetex, GTX70224; 1:10000); ATR (Bethyl Laboratories, A300-890 
137A; 1:1000), pS345-CHK1 (Cell Signaling Technology, 2341; 1:100), pS4/S8-RPA2 891 
(Bethyl Laboratories, A300-245A; 1:1,000), pS966-SMC1 (Bethyl Laboratories, A300-892 
050A; 1:1,000), SMC1 (Bethyl Laboratories, A300-055A; 1:1,000), Treslin (Bethyl 893 
Laboratories, A303-472A; 1:1,000); TOPBP1 (Bethyl Laboratories; A300-111A; 1:1000); 894 
Vinculin (Sigma-Aldrich, V9264; 1:1,000); α-Tubulin (Sigma-Aldrich, T5168; 1:4000); GFP 895 
(Roche, 11814460001; 1:500). The polyclonal anti-DONSON antibody was generated by 896 
immunising rabbits with a GST-fusion protein encoding aa 1-125 of human DONSON. 897 
Antibody was affinity-purified from rabbit sera (Eurogentec) and specificity established 898 
using lysates from patient cells and DONSON siRNA-transfected cells.   899 
 900 
Loading controls for all blots derive from reprobing the same membrane, except for 901 
phospho-antibody blots, where paired gels were run simultaneously, and blotted in parallel 902 
for phosphorylated and total proteins. 903 
 904 
Immunofluorescence and fluorescent microscopy. 905 
siRNA transfected HeLa cells or passage-matched TERT-immortalized fibroblasts were 906 
seeded on coverslips 24 h before extraction/fixation. To visualise cells undergoing DNA 907 
replication, cells incubated in medium containing 10 μM EdU for 10-30 min prior to 908 
harvesting. To remove soluble proteins before immunofluorescence, cells were pre-909 
extracted for 10 min on ice with ice-cold buffer (25 mM HEPES, pH 7.4, 50 mM NaCl, 1 910 
mM EDTA, 3 mM MgCl2, 300 mM sucrose and 0.5% Triton X-100) and then fixed with 4% 911 
paraformaldehyde for 15 min. For analysis of cells transfected with GFP-tagged protein, 912 
cells were fixed and permeabilised by incubation with ice-cold methanol for 20 minutes. 913 
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 914 
EdU immunolabeling was performed using Click-iT EdU Imaging Kit (Invitrogen, C10337) 915 
according to the manufacturer's protocol. Cells were stained for 53BP1 (Novus Biologicals, 916 
NB100-304; 1:1,000) and/or γH2AX (Millipore, 05-636; 1:1000) and stained with secondary 917 
antibodies conjugated to Alexa Fluor-568 (Life Technologies) and DAPI. 918 
 919 
For quantification of signal-integrated densities of γH2AX staining, cells were stained with 920 
an antibody specific to γH2AX (Millipore, 05-636; 1:1000), images were visualized using a 921 
Zeiss Axioplan 2 microscope with iVision software (BioVision Technologies) and captured 922 
using a 40× oil-immersion objective. For quantification of signal-integrated densities of 923 
RPA staining, cells were stained with RPA2 antibody (Millipore, NA18; 1:200), images 924 
were visualized using a Nikon Eclipse Ni microscope with NIS-Elements software (Nikon 925 
Instruments) and captured using a 100× oil-immersion objective. Nuclei were segmented 926 
on the basis of DAPI staining and then signal-integrated density of γH2AX or RPA staining 927 
quantified for each nuclear region using ImageJ software (US National Institutes of Health). 928 
For quantification of γH2AX staining, more than 100 EdU positive cells and 50 EdU 929 
negative cells were analyzed per experiment per condition, and for quantification of RPA 930 
staining, more than 200 cells were analyzed per experiment per condition. Exposure time, 931 
binning, microscope settings and light source intensity were kept constant for all the 932 
samples in all cases. 933 
 934 
For quantification of native BrdU foci cells were incubated in medium containing 10 μM 935 
BrdU for 24 h prior to harvesting. Six hours prior to harvesting, 2 mM HU was added to the 936 
media. To visualise ssDNA foci, cells were extracted for 10 min on ice with ice-cold buffer 937 
(25 mM HEPES, pH 7.4, 50 mM NaCl, 1 mM EDTA, 3 mM MgCl2, 300 mM sucrose and 938 
0.5% Triton X-100) and then fixed with 4% paraformaldehyde for 15 min. After fixation, 939 
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cells were washed with PBS and blocked in 3% FCS in PBS for 30 min at room 940 
temperature. ssDNA was visualised using a BrdU antibody (Abcam, ab6326; 1:500).  To 941 
denature DNA cells were incubated in 2 M HCl in PBS for 30 min prior to addition of the 942 
BrdU antibody. Images were acquired as for γH2AX quantification and foci were quantified 943 
using ImageJ-based script. Nuclei were defined on the basis of DAPI staining and native 944 
BrdU foci were detected using "Find maxima" function of ImageJ within each nuclear 945 
region. Exposure time, binning, microscope settings, light source intensity and the noise 946 
level in “Find maxima” function were kept constant for all the samples within each 947 
individual experiment. More than 100 cells were analyzed per experiment per condition. 948 
 949 
Metaphase spreads 950 
Chromosomal aberrations were scored in Giemsa-stained metaphase spreads as 951 
previously described56. Briefly, demecolcine (Sigma Aldrich) was added at a final 952 
concentration of 0.2 µg/ml 4 h prior to harvesting. Cells were harvested by trypsinisation, 953 
subjected to hypotonic shock for 1 hour at 37°C in 0.3 M sodium citrate and fixed in 3:1 954 
methanol:acetic acid solution. Cells were dropped onto acetic acid humidified slides, 955 
stained for 15 minutes in Giemsa-modified solution (Sigma; 5% v/v in H2O) and washed in 956 
water for 5 minutes. 957 
 958 
DNA fibre spreading assay 959 
Passage-matched primary, TERT-immortalized fibroblasts or siRNA transfected HeLa cells 960 
were pulse labeled with CldU for 20 min, washed with media and damaged with 2 mM 961 
hydroxyurea for 2 h before being pulse labeled with IdU for 40 min. Alternatively, 50 ng/ml 962 
mitomycin C was added to the cells 24 h before CldU pulse labeling and left on during 20 963 
min CldU and 20 min ldU pulse labeling. Cells were harvested by trypsinization, and cell 964 
pellets were washed in PBS. 5 × 105 cells were lysed directly onto glass slides using 965 
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spreading buffer (200 mM Tris-HCl, pH 7.5, 50 mM EDTA, 0.5% SDS) and fixed in 966 
methanol/acetic acid (3:1 ratio). Following 2.5 M HCl denaturation, CldU was detected 967 
using rat anti-BrdU (clone BU1/75, ICR1; Abcam, ab6326; 1:750), and IdU was detected 968 
using mouse anti-BrdU (clone B44; BD Biosciences, 347583; 1:750). Slides were then 969 
fixed in 4% paraformaldehyde before immunostaining with secondary antibodies 970 
conjugated to Alexa Fluor-594 or Alexa Fluor-488 (Life Technologies). Labeled DNA fibers 971 
were visualized using a Nikon Eclipse Ni microscope with NIS-Elements software (Nikon 972 
Instruments). Images were captured using 40× oil-immersion objectives and were 973 
recoloured and analyzed using ImageJ software (US National Institutes of Health). For 974 
quantification of replication structures, at least 400 structures were counted per experiment. 975 
Tract lengths were measured using ImageJ (National Institutes of Health; 976 
http://rsbweb.nih.gov/ij/). To calculate fork velocity, arbitrary length values were converted 977 
into micrometers using the scale bars created by the microscope, with 1 μm equivalent to 978 
2.59 kb59. Replication fork speed (kb/min) was then determined by dividing the length of 979 
CldU and IdU tracks (in kb) from ongoing forks by the pulse time. 980 
 981 
FACS analysis 982 
For BrdU analysis, HeLa cells were pulse labeled with 10 μM BrdU for 30 min before 983 
fixation with 70% ethanol at −20 °C for 16 h. Cells were then digested with 1 mg/ml pepsin 984 
and denatured with 2 M HCl before washing with PBS and blocking in 0.5 % BSA, 0.5 % 985 
Tween-20. BrdU labeling was detected using anti-BrdU antibody (Abcam, ab6326; 1:75) 986 
and FITC-conjugated anti-rat secondary antibody. DNA content was assessed by staining 987 
with 50 μg/ml propidium iodide. Cells were sorted on a BD Biosciences FACS Aria II and 988 
data were analyzed using FlowJo software (v7.6.1, Tree Star).  989 
 990 
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For mitotic analysis and immuno-detection of phospho-histone H3 (Ser10), HeLa cells 991 
were harvested, fixed, permeabilised 24 h post exposure to HU or MMC, as previously 992 
described56. Cells were analysed using an Accuri flow cytometer (BDBiosciences) in 993 
conjunction with CFlowplus software. Data represents that obtained from at least 30,000 994 
cells. 995 
 996 
Immunoprecipitation and GFP-Trap 997 
293FT cells transfected with plasmids encoding GFP-DONSON or GFP were untreated, or 998 
exposed to 2 mM HU for 16 h and harvested. Cells were then incubated in lysis buffer (150 999 
mM NaCl, 50 mM Tris HCl pH7.5, 2 mM MgCl2, 1 % NP40, 90 U/ml Benzonase (Novagen) 1000 
and Protease Inhibitor Cocktail EDTA free (Roche)) for 30 min with rotation at 4 °C. The 1001 
resultant cell lysates were pre-cleared at 44,000 rpm at 4 °C for 30 min. 1002 
 1003 
For immunoprecipitations, 3 mg of lysate was immunoprecipitated with 5 µg of antibody, 1004 
immune complexes collected with Protein A-Sepharose (Sigma-Aldrich). Complexes were 1005 
washed with wash buffer (150 mM NaCl, 50 mM Tris HCl pH 7.5, 0.5 % NP40, and 1006 
Complete Protease Inhibitor Cocktail (Roche)) and analysed by SDS-PAGE.  1007 
 1008 
For GFP-Trap, 3 mg lysates were incubated with GFP-Trap agarose beads (ChromoTek) 1009 
at 4 °C for 5 h. The resulting GFP-Trap complexes were washed with wash buffer as 1010 
above and analysed by SDS-PAGE. Experiments were carried out in the presence of 1011 
Benzonase Nuclease to exclude the possibility of interactions being mediated by DNA. 1012 
 1013 
For mass spectrometry analysis, GFP or GFP-DONSON were isolated from tetracycline 1014 
induced, or uninduced, Flp-In T-REx HeLa cell extracts by incubation with GFP-trap 1015 
magnetic agarose beads (Chromotek) for 2 hours on a Kingfisher Duo robotic handling 1016 
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station (Thermo). Asynchronous cells and S-phase accumulated cells, using a 24 h 1017 
treatment with 2 mM HU, were analysed. On-bead digest and mass spectrometry were 1018 
performed as described60. Data represents three independent experiments for each 1019 
condition, analysed by back-to-back MS and quantified by Label free quantification (LFQ). 1020 
Proteins were identified and quantified with the MaxQuant 1.5 software suite by searching 1021 
against the Uniprot human database. M(ox) and protein N-terminal acetylation were set as 1022 
variable, and carbamylation as a fixed modification, with a 1 % FDR. Contaminants and 1023 
reverse data base hits were deleted. Protein significantly enriched by GFP-DONSON were 1024 
selected on the basis of p-value <0.05, and >2 fold change from asynchronous to S-phase, 1025 
as identified by Student t-test and ratio cut-off against the respective negative control LFQ 1026 
data as determined by MaxQuant (p<0.05; 2-fold). 1027 
 1028 
Proximity ligation assay (PLA). 1029 
PLA was carried out as described in5,56. Briefly, cells from GFP or GFP-DONSON Flp-In T-1030 
REx HeLa cell lines were treated with 1ug/ml doxycycline and fixed/extracted after 24 h. 1031 
For PCNA visualisation, cells were fixed with methanol at -20 °C for 10 min followed by a 5 1032 
min extraction in 0.3% Triton-X100 in PBS. For RPA visualisation, cells were pre-extracted 1033 
in nuclear extraction buffer for 5 minutes on ice, and fixed in 3.6% paraformaldehyde for 1034 
10 minutes at room temperature. Cells were then incubated in anti-PCNA (PC10, 1:500, 1035 
Santa Cruz) or anti-RPA (NA18; 1:500; Merck-Millipore) antibodies along with anti-GFP 1036 
antibody (ab6556, 1:500, Abcam), and in situ proximity ligation was performed using a 1037 
Duolink Detection Kit (Sigma Aldrich). Nuclear foci were imaged using a Nikon Eclipse Ni-1038 
U microscope equipped with a 100X oil lens in conjunction with a Zyla camera, and 1039 
images were acquired using Elements software (Nikon). More than 200 cells were 1040 
analysed per experiment per condition.  1041 
 1042 
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Fluorescence Cross-Correlation Spectroscopy (FCCS)  1043 
HeLa cells stably expressing GFP-DONSON and mCherry-PCNA (construct kindly 1044 
provided by C. Lukas, Copenhagen; referred to as RFP-PCNA) were used for FCCS. For 1045 
all details on Fluorescence Microscopy Imaging and FCS/FCCS, refer to Supplementary 1046 
Note. 1047 
 1048 
Statistical Analyses 1049 
Statistical differences were analyzed by: two-tailed Student T-Test (Fig. 3b, 3d, 3f, 4f, 4g, 1050 
5b-d, 5f, 6a, 6e, 6f, 7b, 7d and Supplementary Fig. 5c, 8b, 9a, 12c, 13i, 14c, 16a-c, 17a-1051 
c, 19, 20, 21); Mann-Whitney rank sum test (Fig. 3e, 6c, 7c and Supplementary Fig. 12b, 1052 
15a, 15c); and Chi-Squared Test (Fig 4c, 6g and Supplementary Fig. 16d). n refers to 1053 
number of independent experiments unless indicated. Error bars represent standard error 1054 
of the mean (s.e.m.) unless specified. 1055 
 1056 
Data Availability  1057 
The NGS data used in the manuscript can be obtained from the European Genome-1058 
phenome Archive (EGA) under accession EGAS00001002224. NGS datasets on patients 1059 
P14-P18, p21 are not available due to institutional IRB restrictions. The mass spectrometry 1060 
proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE 1061 
partner repository with the dataset identifier PXD005690.  1062 
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Table 1:  Biallelic DONSON mutations identified in 29 individuals 
 
Patient Country of Origin Mutation 1 Mutation 2 Segregation 
P1-1 Italy c.1251_1256delCTCTAA, p.Asn417_Ser418del haplotype Het, M 
P1-2 Italy c.1251_1256delCTCTAA, p.Asn417_Ser418del haplotype Het, M 
P2 UK c.877C>T, p.Arg293* haplotype Het, M, P 
P3 UK c.1254dupT, p.Lys419* haplotype Het, M, P 
P4 UK c.1686dupT, p.Asn563* haplotype Het, nps 
P5 Somalia c.832T>C, p.Cys278Arg AND/OR c.845A>G, p.Tyr282Cys haplotype Het, M, P 
P6 USA c.1282C>T, p.Gln428* haplotype Het, M, P 
P7 USA c.1282C>T, p.Gln428* haplotype Het, nps 
P8 Italy c.1474_1475delCA, p.Gln492Glufs*18 c.786-7T>C Het, M, P 
P9 Turkey c.876C>G, p.Phe292Leu c.1047-9A>G (SS) Het, M 
P10-1 India c.1628_1630dupAAA, p.Gln543_Ile544insLys c.1032C>T, p.Ser344Ser (SS) Het, M, P 
P10-2 India c.1628_1630dupAAA, p.Gln543_Ile544insLys c.1032C>T, p.Ser344Ser (SS) Het, M, P 
P11 Saudi Arabia c.786-22A>G (SS) c.786-22A>G (SS) Hom, M, P 
P12 Saudi Arabia c.786-22A>G (SS) c.786-22A>G (SS) Hom, nps 
P13-1 Palestine c.1337T>C, p.Met446Thr c.1337T>C, p.Met446Thr Hom, M, P 
P13-2 Palestine c.1337T>C, p.Met446Thr c.1337T>C, p.Met446Thr Hom, M, P 
P13-3 Palestine c.1337T>C, p.Met446Thr c.1337T>C, p.Met446Thr Hom, M, P 
P14 Saudi Arabia c.786-22A>G (SS) c.786-22A>G (SS) Hom, M, P 
P15 Saudi Arabia c.786-22A>G (SS) c.786-22A>G (SS) Hom, M, P 
P16 Saudi Arabia c.786-22A>G (SS) c.786-22A>G (SS) Hom, M, P 
P17 Saudi Arabia c.786-22A>G (SS) c.786-22A>G (SS) Hom, M, P 
P18-1 Saudi Arabia c.786-22A>G (SS) c.786-22A>G (SS) Hom, M, P 
P18-2 Saudi Arabia c.786-22A>G (SS) c.786-22A>G (SS) Hom, M, P 
P18-3 Saudi Arabia c.786-22A>G (SS) c.786-22A>G (SS) Hom, M, P 
P19 Turkey c.1297C>T, p.Pro433Ser c.1297C>T, p.Pro433Ser Hom, M, P 
P20-1 South Africa c.1254dupT, p.Lys419* c.1510G>A, p.Glu504Lys Het, M, P 
P20-2 South Africa c.1254dupT, p.Lys419* c.1510G>A, p.Glu504Lys Het, M, P 
P21-1 Saudi Arabia c.1047-9A>G (SS)  c.1047-9A>G (SS) Hom, M, P 
P21-2 Saudi Arabia c.1047-9A>G (SS)  c.1047-9A>G (SS)  Hom, M, P 
  
‘Haplotype’ indicates the presence of three co-segregating variants: c.82A>C (p.Ser28Arg); c.786-33A>G; 
c.1466A>C (p.Lys489Thr). Hom, homozygous in affected individual; Het, compound heterozygous in affected 
individual; M, mutation identified in mother; P, mutation identified in father; nps, no parental samples available; 
SS, Splice site mutation. Reference sequence, NM_017613.3. 
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